Table 3.

Outcomes in tocilizumab and anakinra recipients.

	All patients			After propensity score
	Anakinra (n:120)	Tocilizumab (n:240)	p	Anakinra (n:106)	Tocilizumab (n:106)	p
Length of hospital stay after treatment initiation, days, median (IQR)	12 (12)	11 (9)	0.027	11 (11)	10 (8)	0.03
Length of hospital stay after treatment ends, days, median (IQR)	4 (12)	9 (9)	<0.0001	4 (12)	8.5 (9)	<0.0001
Rate of invasive mechanical ventilation, n(%)	32 (26.7)	68 (28.3)	0.73	25 (23.6)	30 (28.3)	0.53
Rate of intensive care unit admission, n(%)	42 (35)	160 (66.7)	<0.0001	35 (33)	70 (66)	<0.001
Mortality, n(%)	17 (14.2)	55 (22.9)	0.05	12 (11.3)	25 (23.6)	0.029

n:number; IQR: interquartile range